@article {1018, title = {Preliminary Assessment of Glycemic Control and Body Fat Reduction Effects of Terminalia chebula Retz. Extract on Pre-diabetic Subjects}, journal = {Pharmacognosy Research}, volume = {14}, year = {2022}, month = {December 2021}, pages = {5-11}, type = {Original Article}, chapter = {5}, abstract = {

Background: Terminalia chebula Retz. (Combretaceae) is a medicinal herb using in traditional medicine worldwide and has hypoglycemic effects in animal models. Objectives: The present study was a double-blind, placebo-controlled trial designed to study the effect of T. chebula fruit water extract (TFWE) in pre-diabetic subjects. The efficacy of TFWE and placebo were compared in terms of reducing fasting blood sugar (FBS) levels, body mass indexes (BMI), body circumferences and skinfold thicknesses. Adverse events of TFWE intervention were also investigated. Materials and Methods: TFWE was phytochemically quantitated by HPLC analysis and its inhibitory action on alpha-glucosidase. In a clinical study, 80 pre-diabetic healthy subjects were classified according to BMI as normal weight and overweight and each group was further divided into 2 groups. The treatment group received 2 capsules of TFWE 500 mg, 2 times per day, before meals for 8 weeks and the control group received 2 placebo capsules, taken orally as the treatment group. Data was collected at week 0, 4 and 8 of the study. Results: For overweight participants receiving TFWE, the mean FBS levels were significantly lower than that of the placebo group (p = 0.026) at week 8. Visceral fat levels also showed a significant reduction (p = 0.039) compared to the placebo group. TFWE dispensation did not show serious adverse events. Conclusion: The administration of 2,000 mg TFWE per day was considered safe for the pre-diabetic healthy subjects with benefits in obesity management.

}, keywords = {Diabetes, Fasting blood sugar, Obesity, Terminalia, Visceral fat.}, doi = {10.5530/pres.14.1.2}, url = {https://phcogres.com/fulltext/v14i1/105530pres1412.html}, author = {Sansanee Sombattera and Bunleu Sungthong and Prasoborn Rinthong} } @article {391, title = {Ameliorative Effect of Curcumin on Olanzapine-induced Obesity in Sprague-Dawley Rats}, journal = {Pharmacognosy Research}, volume = {9}, year = {2017}, month = {July 2017}, pages = {247-252}, type = {Original Article}, chapter = {247}, abstract = {

Objective: To evaluate the effect of curcumin on olanzapine-induced obesity in rats. Materials and Methods: Sprague-Dawley (SD) rats were used for experiments. The animals were divided into six groups, namely, normal control, olanzapine control, betahistine (10 mg/kg), and curcumin 50, 100, and 200 mg/kg treated groups. Except the normal control group, all other animals were administered with olanzapine 4 mg/kg intraperitoneally to induce obesity. The drugs were administered once daily, per oral for 28 days. During the experiment, body weight changes and behavior alterations were monitored at regular intervals. At the end of the experiment, blood sample was collected from all the experimental animals for biochemical analysis. Part of the liver and kidney tissues was harvested from the sacrificed animals and preserved in neutral formalin for histopathological studies. Results: Curcumin showed a significant reduction in olanzapine-induced body weight gain on the rats and improved the locomotor effects. The effect of curcumin on olanzapine-induced body weight gain is not comparable with that of betahistine. Conclusion: This study has shown metabolic alteration effect of curcumin on olanzapine, an antipsychotic drug, treated SD rats.

}, keywords = {Betahistine, Curcumin, Obesity, Olanzapine}, doi = {10.4103/pr.pr_8_17}, author = {Subramani Parasuraman and Khor Ming Zhen and Urmila Banik and Parayil Varghese Christapher} }